



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C12Q 1/68</b>		A2	(11) International Publication Number: <b>WO 99/09210</b> (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/EP98/05175 (22) International Filing Date: 14 August 1998 (14.08.98)		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 055,863 15 August 1997 (15.08.97) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant (for all designated States except US): INSTITUT PASTEUR [FR/FR]; 28, rue du Docteur Roux, F-75724 Paris Cedex 15 (FR).			
(72) Inventors; and (75) Inventors/Applicants (for US only): PETIT, Christine [FR/FR]; 2, rue Amélie, F-92350 Le Plessis-Robinson (FR). DENOYELLE-GRYSON, Françoise [FR/FR]; 22, rue du 8 mai 1945, F-94110 Arcueil (FR). WEIL, Dominique [FR/FR]; 11, rue de Javel, F-75015 Paris (FR). MARLIN-DUVERNOIS, Sandrine [FR/FR]; 18, avenue J. Binet, F-92000 Colombes (FR). GUESDON, Jean-Luc [FR/FR]; 33, Grande Rue, F-92310 Sèvres (FR).			
(74) Agent: HIRSCH, Denise; Cabinet Lavoix, 2, place d'Estienne d'Orves, F-75441 Paris Cedex 09 (FR).			
(54) Title: A MUTATION WITHIN THE CONNEXIN 26 GENE RESPONSIBLE FOR PRELINGUAL NON-SYNDROMIC DEAFNESS AND METHOD OF DETECTION			
(57) Abstract <p>A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect, wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A MUTATION WITHIN THE CONNEXIN 26 GENE RESPONSIBLE FOR PRELINGUAL NON-SYNDROMIC DEAFNESS  
AND METHOD OF DETECTION

BACKGROUND OF THE INVENTION

The present invention concerns a mutation responsible  
10 for autosomal prelingual non-syndromic deafness and a method  
for the detection of this hereditary sensory defect for  
homozygous and heterozygous individuals. The invention  
concerns more particularly a specific deletion of at least  
one nucleotide in the connexin 26 (Cx 26) gene and especially  
15 in a guanosine rich region, notably between the nucleotides  
27 and 32. The invention is also directed to the use of  
polynucleotide, or fragments thereof, for example as tools  
useful for the *in vitro* detection of a mutation of a gene  
belonging to the Cx26 gene family.

20 Profound or severe prelingual deafness affects one child  
in a thousand in developed countries (Morton NE. Genetic  
epidemiology of hearing impairment. In *Genetics of hearing  
impairment*. (The New York Acad Sci, New York 1991; 630:16-  
31). It is a major handicap as it impedes language  
25 acquisition.

According to studies performed in a U.S. population of  
children with non-syndromic (isolated) prelingual deafness  
and in whom an obvious environmental cause has been excluded,

it is estimated that up to two-thirds of the cases have a genetic basis (Marazita ML, Ploughman LM, Rawlings B, Remington E, Arnos KS, Nance WE. Genetic epidemiological studies of early-onset deafness in the U.S. school-age 5 population. *Am J Med Genet* 1993; **46**:486-91). These forms are mainly sensorineural and are almost exclusively monogenic. The major mode of inheritance is autosomal recessive (DFNB), involving 72% to 85% of cases, this fraction increasing to 90% when only profound deafness is 10 taken into account.

Autosomal recessive prelingual deafness is known to be genetically highly heterogeneous. Estimates of the number of DFNB loci vary from thirty to one hundred (Petit C. Autosomal recessive non-syndromal hearing loss. In *Genetics and 15 Hearing Impairment*. Martini A, Read AP, Stephens D, eds (Whurr, London) 1996; 197-212), for a review), of which fourteen have so far been mapped to the human chromosomes (Petit C. Genes responsible for human hereditary deafness: *symphony of a thousand*. *Nature Genet* 1996; **14**:385-91) for 20 review, (Verhoeven K, Van Camp G, Govaerts PJ, et al. A gene for autosomal dominant non-syndromic hearing loss (DFNA12) maps to chromosome 11q22-24. *Am J Hum Genet* 1997; **60**:1168-74 and Campbell DA, McHale DP, Brown KA, et al. A new locus for non-syndromal autosomal recessive sensorineural hearing loss

(DFNB16) maps to human chromosome 15q21-q22. *J Med Genet* 1997; in press).

A majority of the families attending genetic counseling clinics consist of normal hearing parents with a single deaf 5 child who wish to know the risk of recurrence of the defect.

In most cases, given the major role of environmental causes of prelingual deafness, it is not usually possible even to recognize whether the hearing loss is of genetic origin.

Genetic counseling in such families would be greatly improved 10 by an ability to detect DFNB mutations. In this respect, the high genetic heterogeneity of the condition represents a major obstacle.

After the initial identification of the DFNB1 locus on 13q11 in a large consanguineous Tunisian family (Guilford P, 15 Ben Arab S, Blanchard S, et al. A non-syndromic form of neurosensory, recessive deafness maps to the pericentromeric region of chromosome 13q. *Nature Genet* 1994; 6:24-8), two studies performed on New Zealand/Australian families (Maw MA, Allen-Powell DR, Goodey RJ, et al. The contribution of the 20 DFNB1 locus to neurosensory deafness in a Caucasian population. *Am J Hum Genet* 1995; 57:629-35), and on Italian/Spanish families (Gasparini P, Estivill X, Volpini V, et al. Linkage of DFNB1 to non-syndromic neurosensory autosomal-recessive deafness in Mediterranean families. *Eur*

*J Hum Genet* 1997; 5:83-8) suggested that this locus might be a major contributor to prelingual deafness in these populations, although individual lod scores obtained in these families were not significant owing to the small size of 5 these families.

Recently, the Cx26 gene, which encodes a gap junction protein, connexin 26, has been shown to underlie DFNB1 deafness. Two different G->A substitutions resulting in premature stop codons in three DFNB1 linked consanguineous 10 Pakistani families have been reported (Kelsell DP, Dunlop J, Stevens HP, et al. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. *Nature* 1997; 387:80-3). These two substitutions were identified, respectively, at codon 77 and at codon 24. This result has offered the 15 opportunity directly to assess this hypothesis.

The difficulties encountered in genetic counseling for prelingual non-syndromic deafness due to the inability to distinguish genetic and non-genetic deafness in the families presenting a single deaf child was one of the reasons that 20 led the inventors to undertake a characterization of the spectrum and prevalence of mutations present in the Cx26 gene in 35 families from several parts of the world with autosomal recessive prelingual deafness.

SUMMARY OF THE INVENTION

The determination of a mutation in the Cx26 gene has notably rendered possible the use of a detection probe as a  
5 tool for the identification of a specific form of autosomal prelingual non-syndromic deafness, and more particularly the useful role of a newly identified 30delG (a G deletion at position 30; position 1 being the first base of the initiator codon) mutation in such families. This invention establishes  
10 that the contribution of the DFNB1 locus predominantly results essentially from the 30delG mutation. It is now believed that the 30delG accounts for about three-quarters of all recessive DFNB1 mutations.

The invention is thus intended to provide a purified  
15 polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect. The mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness.

20 The invention also provides oligonucleotides comprising of 15 to 50 consecutive nucleotides of the mutated purified polynucleotide that are useful as primers or as probes.

In addition, the invention aims to supply a method and  
a kit for the detection of the hereditary sensory defect for  
25 homozygous as heterozygous individuals.

According to the invention, the purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which encodes in a wild form a polypeptide implicated in hereditary sensory defect, presents a mutation 5 responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide.

By mutation, according to the invention it means a specific deletion of at least one nucleotide. Thus, a 10 mutated sequence means a polynucleotide sequence comprising at least a mutation.

A chain of nucleotides, according to the invention, means a polynucleotide, which encodes not necessarily a polypeptide, but which presents between 27 and 2311 15 nucleotides linked together.

The invention particularly concerns a purified polynucleotide wherein, the specific mutation is a deletion located in a region encoding connexin 26 of chromosome 13q11-12, preferably located in a guanosine rich region starting at 20 nucleotide 27 preferably at nucleotide 30, and extending to nucleotide 32 or nucleotide 35, all the recited nucleotides being inclusive. More particularly according to the invention, the specific deleted purified polynucleotide encodes for a truncated polypeptide.

By truncated polypeptide, according to the invention it means a fragment of the polypeptide, which does not present the properties of the wild form of the polypeptide either in length, in amino acid composition, or in functional properties.

A preferred embodiment of a specific deletion is a guanosine deletion at position 30, also called "30delG mutation". Another preferred embodiment of the specific deletion is a 38 bp deletion beginning at position 30.

The invention also includes a purified polynucleotide, which hybridizes specifically with any one of the polynucleotides as defined above under the following stringent conditions: at low temperatures between 23°C and 37°C, in the presence of 4 x SSC buffer, 5 x Denhardt's solution, 0.05% SDS, and 100µg/ml of salmon sperm DNA. (1 x SSC corresponds to 0.15 M NaCl and 0.05M sodium citrate; 1 x Denhardt's solution corresponds to 0.02% Ficoll, 0.02% polyvinylpyrrolidone and 0.02% bovine serum albumin).

The invention also concerns an oligonucleotide useful as a primer or as a probe comprising 15 to 50 consecutive nucleotides of the polynucleotide according to any one of the polynucleotides as defined above. The oligonucleotide sequence is selected from the following group:

- A first couple:

5'-TCTTTCCAGAGCAAACCGCC (SEQ ID No. 1)-3'

5'-TGAGCACGGGTTGCCTCATC (SEQ ID No. 2)-3'.

The length of the PCR product has been obtained from 285 bp in length;

- 5 - A second couple allowing to explore the other part of the reading frame:

5'-GACACGAAGATCAGCTGCAG (SEQ ID No. 3)-3'

5'-CCAGGCTGCAAGAACGTGTG (SEQ ID No. 4)-3'

- A third couple:

10 5'-CTAGTGATT CCT GTG TT GTG TGC (SEQ ID No. 9)-3'; and

5' ATAATGCGAAAAATGAAGAGGA (SEQ ID No. 10)-3' and

- A fourth couple:

5'-CGCCCCGCCGCGCCCCCGCGCCCGGCCGCCCCCGCCCCCTAGTGATT CCT  
GTG TT GTG TGC (SEQ ID No. 14)-3'; and

15 5' ATAATGCGAAAAATGAAGAGGA (SEQ ID No. 10)-3'.

Another oligonucleotide useful as a probe is selected from the following group:

5'-AGACGATCCTGGGGGTGTGAACAAA (SEQ ID No. 5)-3'

20 5'-ATCCTGGGGGTGTGA (SEQ ID No. 6)-3'

5'-AGACGATCCTGGGGCTCACCGTCCTC (SEQ ID No. 7)-3'.

In addition, the invention concerns a method for the detection of an hereditary sensory defect, namely autosomal prelingual non-syndromic deafness, for homozygous as 25 heterozygous individuals in a biological sample containing DNA, comprising the steps of:

- a) bringing the biological sample into contact with a oligonucleotide primers as defined above, the DNA contained in the sample having been optionally made available to hybridization and under conditions permitting a hybridization 5 of the primers with the DNA contained in the biological sample;
- b) amplifying the DNA;
- c) revealing the amplification products;
- d) detecting the mutation.
- 10 Step d) of the above-described method may comprise a Single-Strand Conformation Polymorphism (SSCP), a Denaturing Gradient Gel Electrophoresis (DGGE) sequencing (Smith, L.M., Sanders, J.Z., Kaiser, R.J., Fluorescence detection in automated DNA sequence analysis. *Nature* 1986; 321:674-9); a 15 molecular hybridization capture probe or a temperature gradient gel electrophoresis (TGGE).
- Step c) of the above-described method may comprise the detection of the amplified products with an oligonucleotide probe as defined above.

20 According to the invention, a biological sample can be a blood sample extracted from people suffering from any kind of deafness with any criteria as follows: neurosensorial or mixed isolated deafness, advanced or not, at any degree of severity, concerning familial or sporadic case, or

individuals exposed to noise, or individuals suffering from a low acoustic, or individuals susceptible to carry an anomaly in the gene, or from an embryo for antenatal diagnostic.

5 Another aim of the invention comprises a method for the detection of an hereditary sensory defect, the autosomal prelingual non-syndromic deafness, for homozygous and heterozygous individuals in a biological sample containing DNA, comprising the steps of:

10 a) bringing the biological sample into contact with an oligonucleotide probe according to the invention, the DNA contained in the sample having been optionally made available to hybridization and under conditions permitting a hybridization of the primers with the DNA contained in the  
15 biological sample; and

b) detecting the hybrid formed between the oligonucleotide probe and the DNA contained in the biological sample.

Step b) of the above-described method may consist in a  
20 single-strand conformation. Polymorphism (SSCP), a denaturing gradient gel electrophoresis (DGGE) or amplification and sequencing.

The invention also includes a kit for the detection of an hereditary sensory defect, the autosomal prelingual non-

syndromic deafness, for homozygous as heterozygous individuals, said kit comprising:

- a) oligonucleotides according to the invention;
- b) the reagents necessary for carrying out DNA amplification; and
- c) a component that makes it possible to determine the length of the amplified fragments or to detect a mutation.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10

This invention will be more described in greater detail by reference to the drawings in which:

Figure 1 depicts the results of temperature gradient gel electrophoresis for detection of mutants in which:

- 15 Lanes 1 and 2: DNA from normal patients.
- Lanes 3 and 4: DNA from homozygous patients with 30delG mutation.
- Lanes 5 and 6: DNA from heterozygous patients.
- Lane 7: PCR control without DNA.
- 20 Lane 8: PCR fragment amplified from a normal DNA and hybridized with a standard DNA fragment harboring the 30delG mutation.
- Lane 9: PCR fragment amplified from a mutant homozygous DNA and hybridized with a normal standard DNA fragment harboring the guanine 30.

25

#### DETAILED DESCRIPTION OF THE INVENTION

30

Prelingual non-syndromic (isolated) deafness is the most frequent hereditary sensory defect in children. The inheritance in most is autosomal recessive. Several dozens of genes might be involved, only two of which, DFNB1 and DFNB2,

have so far been identified (Kelsell, D.P., et al., Connexin 26 mutations in hereditary non-syndromic sensorineural deafness. *Nature* 1997; 387:80-3; Liu, X-Z, et al., Mutations in the myosin VIIA gene cause non-syndromic recessive 5 deafness, *Nature Genet* 1997; 16:188-90; and Weil, D., et al., The autosomal recessive isolated deafness, DFNB2, and the Usher 1B syndrome are allelic defects of the myosin-VIIA. *Nature Genet* 1997; 16:191-3). A search was made searched for mutations in the gene encoding connexin 26, Cx26, which has 10 recently been shown to be responsible for DFNB1. Mutation analysis of Cx26 was performed by PCR amplification on genomic DNA and sequencing of the single coding exon.

Example 1: Patients

15       Thirty-five affected families from various geographical regions, mainly France, New Zealand and Australia, Tunisia and Lebanon, were studied. They could be classified into three categories: (1) consanguineous families each having a significant linkage to the DFNB1 locus; (2) small non- 20 consanguineous families in which linkage analysis was compatible with the involvement of DFNB1; and (3) small families in which no linkage analysis had been undertaken.

     The first category consists of six large families living in geographically isolated regions. Five were from Tunisia,

two from the north and three from the south. Linkage to the DFNB1 locus in the two families from northern Tunisia (families 20 and 60) had previously been reported (Guilford P, Ben Arab S, Blanchard S, et al., A non-syndromic form of neurosensory, recessive deafness maps to the pericentromeric region of chromosome 13q. *Nature Genet* 1994; 6:24-8); the three families from southern Tunisia (S15, S19 and ST) and the family from Lebanon (LH) comprise total of three, five, two, and five deaf children, respectively, the deafness being of severe or profound degree. The marriages were between first cousins (S15, ST and LH) and between first and second cousins (S19). Linkage analysis of these six families resulted in individual lod scores ranging from 2.5 to 10 with polymorphic markers from the DFNB1 region (D13S175, D13S141, D13S143 and D13S115).

The second category of patients comprises seven New Zealand families with at least two deaf siblings (families 51, 1160, 1548, 1608, 1773, 1873, 1877) and one Australian (9670) family. Family 1608 was atypical in that four siblings sharing the same DFNB1 marker haplotypes had a mild to moderate deafness (severe at high frequency), with the child of one of them being profoundly deaf. In family 1873, the unrelated parents (individuals II.2 and II.3) were deaf as well as their two children, and we have therefore considered

this as two families, bringing to nine the total of independent families. Apart from families 1608 and 1873, no parent acknowledged any hearing impairment. These nine families showed cosegregation between deafness and 5 polymorphic markers of the DFNB1 region with maximum individual lod scores ranging from 0.6 to 1.2. Ten other families in the original study of Maw et al. (Maw MA, Allen-Powell DR, Goodey RJ, et al. The contribution of the DFNB1 locus to neurosensory deafness in a Caucasian population. Am 10 J Hum Genet 1995; 57:629-35) had shown no cosegregation and one other cosegregating family was not tested for Cx26 mutations. The New Zealand families were all of Caucasian origin with no known Polynesian admixture. According to the antecedent family names, the ancestral proportion among the 15 families reflected that of the general Caucasian New Zealand population with the great predominance being of Anglo-Celtic patrimony and a small fraction due to migration from continental Europe. Neither parental consanguinity, nor links between any of the families were recognized. In the 20 Australian case, the father was from Northern Ireland and the mother from Yorkshire, England.

The third category is composed of nineteen families living in France and two in New Zealand, each with at least two children having a severe to profound deafness. No parent

acknowledged any hearing impairment, except for the mother in family P16 and the father in family P17 who had moderate and progressive high-frequency hearing loss. Five of these families had foreign ancestors from Lebanon (family P3),  
5 Turkey (family P4), Portugal (family P9), Algeria (family P14) and Poland (father in family P16). In two of the families (P7 and P14), the parents were distantly related.

Example 2: Amplification of the coding exon of Cx26  
10 PCRs were carried out on genomic DNA using a set of primers that allowed the amplification of the entire coding sequence of the Cx26 gene, which consists of a single coding exon (Kelsell DP, Dunlop J, Stevens HP, et al. Connexin 26 mutations in hereditary non-syndromic sensorineural deafness.  
15 *Nature* 1997; 387: 80-3). Primer sequences were as follows:

5'-TCTTTCCAGAGCAAACCGCC (SEQ ID No. 1)-3' and

5'-TGAGCACGGGTTGCCTCATC (SEQ ID No. 2)-3'.

PCR conditions were: 35 cycles of 95°C, 1 min; 58°C, 1 min; 72°C, 2 min. The PCR product obtained was 777 bp in length.

20

Example 3: DNA sequencing

Sequencing of the PCR products was performed as previously described (Smith LM, Sanders JZ, Kaiser RJ, et

al., Fluorescence detection in automated DNA sequence analysis, *Nature* 1986; 321:674-9) using the dideoxy chain terminator method on an Applied Biosystems DNA sequencer ABI373 with fluorescent dideoxynucleotides. The primers used  
5 were the same as those for the PCR amplification plus two internal primers

5'-GACACGAAGATCAGCTGCAG (SEQ ID No. 3)-3' and  
5'-CCAGGGCTGCAAGAACGTGTG (SEQ ID No. 4)-3'.

10       Example 4: Mutations in consanguineous Tunisian and Lebanese DFNB1 families

In these families the involvement of the DFNB1 locus could be demonstrated by linkage analysis. In four of the five families from Tunisia (S15, S19, 20, and 60) and in the  
15 Lebanese family (LH), the same mutation was detected in all affected children on both Cx26 alleles, namely, a deletion of a guanosine (G) in a sequence of six G extending from position 30 to 35 (position 1 being the first base of the initiator codon) (Table 1). This mutation is hereafter referred to as 30delG mutation according to the nomenclature proposed by Beaudet and Tsui ((Beaudet AL, Tsui L-C. A suggested nomenclature for designating mutations, *Hum Mutation* 1993; 2: 245-8)). It creates a frameshift, which results in a premature stop codon at nucleotide position 38.

The mutation segregating in the fifth family from Tunisia (ST) was identified as a G to T transversion at nucleotide position G39 creating a premature stop codon (GAG->TAG) at codon 47, and was designated E47X. In each family, normal hearing parents were found to be heterozygous for the corresponding mutation.

5                   Example 5: Mutations in small nonconsanguineous New Zealand and Australian families consistent with DFNB1  
10 linkage

In these families, segregation analysis has previously been reported as compatible with the involvement of the DFNB1 locus (Maw MA, Allen-Powell DR, Goodey RJ, et al. The contribution of the DFNB1 locus to neurosensory deafness in 15 a Caucasian population. *Am J Hum Genet* 1995; 57: 629-35).

The deaf individuals from five of the nine families (51, 1160, 1608 (III.20), 1873 (II.3) and 1877) were homozygous for the 30delG mutation. The deaf children from family 1773 were heterozygous for 30delG. Deaf individual II.2 from 20 family 1873 (see "subjects" and Table 1) was heterozygous for a deletion of 38 bp beginning at nucleotide position G30, designated 30del38. No other mutation was detected in the deaf children of family 1773 and the deaf individual (II.2) in family 1873. Nevertheless, in this last individual, a

deletion of the polymorphic marker immediately proximal to the Cx26 gene (locus D13S175) had previously been observed (Maw MA, Allen-Powell DR, Goodey RJ, et al. The contribution of the DFNB1 locus to neurosensory deafness in a Caucasian 5 population. *Am J Hum Genet* 1995; 57: 629-35), which may indicate that a DNA rearrangement has impaired the functioning of the other Cx26 allele of the gene in cis. In family 9670, compound heterozygosity for a missense mutation (R184P) and an in frame single-codon deletion (delE138) was 10 observed in affected siblings. In only one family (1548) was no Cx26 mutation detected. Results are summarized in Table 1.

Example 6: Mutations in small families uncharacterized 15 for DFNB1 linkage living in France and New Zealand

Nineteen families (P1 to 17, L14190 and L13131) living in France and two in New Zealand (families 1885 and 2254) were studied. In these families, cosegregation of the deafness with polymorphic markers had not been analysed. Deaf 20 children from six of the twenty-one families (P1, P3, P5, P9, P10, and P16) were found to be homozygous for the mutation 30delG. In five additional families (P6, P11, P14, P17, and 1885), deaf children were heterozygous for this mutation; no

other mutation was detected in these families. In the ten remaining families, no mutation in the Cx26 gene was found.

5       Example 7:      Molecular hybridization using allele-specific capture probes

Molecular hybridization capture probe (see, e.g., D. Chevrier et al. PCR product quantification by non-radioactive hybridization procedures using an oligonucleotide covalently bound to microwells. Molecular and Cellular Probes 1993; 7: 187-197 and D Chevrier et al. Rapid detection of *Salmonella* subspecies I by PCR combined with non-radioactive hybridization using covalently immobilized oligonucleotide on a microplate. FEMS Immunology and Medical Microbiology 1995; 15: 10: 245-252 each of which is incorporated by reference herein) permit specific detection of the 30delG mutation. The technique has been adapted to permit rapid diagnosis of prelingual non-syndromic deafness caused by the 30delG mutation. The technique provides certain advantages in a 20 clinical setting because it uses stable, nonradioactive molecules, it can be easily automated, and it is well adapted to large scale analysis.

Using primers designed for PCR amplification, the region of interest in the Cx26 gene is amplified from genomic DNA samples. The primer sequences are as follows:

CONN3: 5'-CTAGTGATTCCCTGTGTTGTGC (SEQ ID No. 9)-3'

CONN4: 5' ATAATGCGAAAAATGAAGAGGA (SEQ ID No. 10)-3'

PCR is performed with the CONN3 (SEQ ID No. 9) and CONN4 (SEQ ID No. 10) primers (1  $\mu$ M each), an aliquot of the DNA to be analyzed (2  $\mu$ l, 100-300 ng), 1.5 mM MgCl<sub>2</sub>, 200  $\mu$ M dNTP, and 5 Taq polymerase. The amplification program consists of the following steps: 1) 95°C, 5 min; 2) addition of enzyme, 95°C, 1 min; 3) 60°C, 1 min (ramp rate = 0.25°C/s); 4) 72°C, 1 min; 5) repeat steps 2 to 4 for 40 cycles; and 6) 72°C, 10 min. PCR products are verified by a rapid gel electrophoresis.

10 The amplified PCR product contains either the normal or the mutant Cx26 sequence. To distinguish between the normal and mutant sequence, two capture probes are designed. The sequences of these two capture probes are as follows:

For detection of normal sequence:

15 CONN6: 5'-AAAAAAAATCCTGGGGGTGTG (SEQ ID No. 11)-3'

For detection of mutant sequence:

CONN7: 5'-AAAAAAAATCCTGGGGGTGTGA (SEQ ID No. 12)-3'

Each capture probe must be 22 nucleotides long. Furthermore, to be efficient, the capture probe must include an A, spacer 20 at its 5' end and a hybridization region of 15 bases. Such a capture probe is able to specifically differentiate the mutant sequence from the normal sequence. Thus, CONN6 (SEQ ID No. 11) is designed to specifically hybridize with the

normal sequence, whereas CONN7 (SEQ ID No. 12) is designed to specifically hybridize with the mutant sequence.

Before attaching the capture probes to a microtiter plate, they are phosphorylated at their 5' ends. The phosphorylation is carried out for 1 hour at 37°C in presence of 20 nmoles of CONN6 (SEQ ID No. 11) or CONN7 (SEQ ID No. 12) oligonucleotides, 100 µM ATP, 10 units T4 polynucleotide kinase in 200 µl of buffer (50 mM Tris-HCl pH 7.4; 10 mM MgCl<sub>2</sub>; 5mM dithiothreitol; and 1 mM spermidine). The mixture is heated for 10 min. at 68°C to inactivate the T4 polynucleotide kinase, then the oligonucleotide is precipitated by adding 145 µl of 10 M CH<sub>3</sub>COONH<sub>4</sub>, 15 µl H<sub>2</sub>O, and 800 µl iced ethanol. After a 30 min. incubation in ice, the mixture is centrifuged for 20 min. at 12,000 × g at 4°C. The resulting pellet is washed with 500 µl iced ethanol (70%) and dissolved in 800 µl of TE buffer. The phosphorylated oligonucleotide concentration is determined by optical density at 260 nm.

Before attaching the phosphorylated oligonucleotides to microplates, they are denatured by heating at 95°C for 10 min. and rapidly cooled in ice to avoid the formation of secondary structure. 500 ng of phosphorylated CONN6 (SEQ ID No. 11) or CONN7 (SEQ ID No. 12) and 1 µl of 1 M 1-

methylimidazole, pH 7, is added to each well of a microplate, which is kept on ice. The total volume of each well is adjusted to 70 µl with distilled water, before adding 30 µl of a cold, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide solution (167 mM). The microplate is covered and incubated for 5 hours at 50°C in an incubator (Thermomix® from Labsystems). After the 5-hour incubation, the microplate is washed three times with a warm solution (50°C) of 0.4 N NaOH containing 0.25% SDS. The microplate is incubated for 5 min. 10 with the same warm solution and washed again with warm NaOH/SDS (50°C). Finally, the microplate is washed five times with TE buffer. The coated microplate can be kept several months at 4°C, if the wells are filled with TE buffer.

15 The amplified sequences from the genomic DNA samples are incubated with a biotinylated detection probe in the coated microplates. Unlike the capture probes, which are allele specific, the detection probe can hybridize with both the normal and mutant sequences. The sequence of the detection 20 probe is:

CONN12: 5'-CAGCATTGGAAAGATCTGGCTCA(SEQ ID No. 13)-3'.  
The amplified sequences and the detection probe, which is biotinylated at its 5' end, are denatured directly in the microplates by successively adding to each well: 95 µl of

water, 5 µl of PCR reaction, 40 µl of biotinylated probe (SEQ ID No. 13) at 22 nM diluted in water, and 14 µl 1 N NaOH.

After 10 min., 21 µl of 1 M NaH<sub>2</sub>PO<sub>4</sub> and 1% Sarkosyl is added to each well to bring the total volume to 175 µl per well.

5 The final concentration of the detection probe is 5 nM. The microplate is covered and incubated overnight at 40°C in an incubator (Thermomix® from Labsystems) and then extensively washed (5 times) with TBS-Tween to remove the excess biotinylated probe (SEQ ID No. 13).

10 An immunoenzymatic method is used to detect the hybridized probe. Each well receives 100 µl of the conjugate (Extravidine - alkaline phosphatase, Sigma E-2636) diluted 1/4000 in TBS-BSA-Tween. The microplate is covered and incubated for 1 hour at 25°C. Following the incubation, the  
15 microplate is washed 5 times with TBS-Tween. Then 200 µl of preheated (37°C) substrate (7.5 mg para-nitro-phenyl-phosphate in 20 ml of the following buffer: 1 M diethanolamine pH 9.8 containing 1mM MgCl<sub>2</sub>) are added to each well. The microplate is covered and incubated for 3 hours at  
20 37°C. The absorbance is measured at 405 nm to determine the specific signal and at 630 nm to determine the background noise.

The hybridization ratio (R) between the signal obtained with CONN6 (SEQ ID No. 11) probe (normal sequence) and that obtained with CONN7 (SEQ ID No. 12) probe ('mutant sequence) is calculated. The calculated R values are used to determine 5 the genotypes of the sample DNA as follows: homozygous for the normal Cx26 sequence ( $R \geq 2$ ), heterozygous for the 30delG mutation ( $0.5 < R < 2$ ), and homozygous for the 30delG mutation ( $R \leq 0.5$ ). The range of the hybridization ratio (R) can be slightly modified when the number of samples 10 increases. The following table represents an example of results obtained with 39 samples.

Hybridization ratio (R)			
Genotype :	Normal	Homozygous 30delG	Heterozygous
5.96	0.48	1.33	
5.43	0.17	1.13	
3.39	0.21	0.73	
4.14	0.16	0.63	
4.09	0.28	1.4	
2.76	0.13	0.73	
2.2	0.21	0.76	
3.97	0.4	0.73	
4.07		1.06	
3			
2.76			
3.66			
3.87			
3.92			
3.26			
5.17			
2.74			
4.51			
6.3			
3.49			
4.05			
3.17			
Number	22	8	9
Mean value	3.91	0.26	0.94
Standard deviation	1.06	0.12	0.29
Range	(6.3 - 2.2)	(0.48 - 0.13)	(1.4 - 0.63)

Example 8: Temperature gradient gel electrophoresis

Temperature gradient gel electrophoresis (TGGE) permits the detection of any type of mutation, including deletions, 5 insertions, and substitutions, which is within a desired region of a gene. (See, e.g. D. Reiner et al. Temperature-gradient gel electrophoresis of nucleic acids: Analysis of conformational transitions, sequence variations and protein-nucleic acid interactions. Electrophoresis 1989; 10: 377-389; 10 E.P. Lessa and G. Applebaum Screening techniques for detecting allelic variation in DNA sequences. Molecular Ecology 1993; 2: 119-129 and A.L. Börresen-Dale et al. Temporal Temperature Gradient Gel Electrophoresis on the D code™ System. Bio-Rad US/EG Bulletin 2133; the entire 15 disclosure of each publication is incorporated by reference herein.) However, TGGE does not permit one to determine precisely the type of mutation and its location.

As in the previously described molecular hybridization technique, the region of interest in the Cx26 gene is first 20 amplified from genomic DNA samples by PCR. The primer sequences are as follows:

CONN2: 5'-CGCCCGCCGCGCCCCGCGCCGGCCGCCGCCGCCCT

AGTGATTCTGTGTTGTGC (SEQ ID No. 14)-3'

CONN4: 5' ATAATGCGAAAAATGAAGAGGA (SEQ ID No. 10)-3'

PCR is performed with 1  $\mu$ M of the CONN2 (SEQ ID No. 14) primer, which has a GC clamp at its 5' end, and 1  $\mu$ M of the CONN4 (SEQ ID No. 10) primer, an aliquot of the DNA to be analyzed (2  $\mu$ l, 100-300ng), 1.5 mM MgCl<sub>2</sub>, 200  $\mu$ M dNTP, and 5 Taq polymerase. The amplification program consists of the following steps: 1) 95°C, 5 min; 2) addition of enzyme, 95°C, 1 min; 3) 60°C, 1 min (ramp rate = 0.25°C/s); 4) 72°C, 1 min; 5) repeat steps 2 to 4 for 40 cycles; and 6) 72°C, 10 min.

Analyzing these PCR amplification fragments by TGGE can 10 differentiate between homozygous (normal or mutant) samples, which produce a single band on a gel, and heterozygous samples, which produce three bands. However, differentiating between genomic samples that are homozygous for the normal sequence and genomic samples that are homozygous for the 15 30delG mutants requires an additional step.

To differentiate normal homozygous versus mutant homozygous samples, an aliquot of the amplified PCR product is mixed with either a known, normal homozygous sample or a known, 30delG mutant homozygous sample and analyzed for 20 heteroduplex formation. If the amplified PCR product derives from a normal, homozygous sample, it will form a heteroduplex with the known, 30delG mutant homozygous sample. On the other hand, if the amplified PCR product derives from a

mutant, homozygous sample, it will form a heteroduplex with the known, normal homozygous sample. To promote heteroduplex formation in these mixtures, they are denatured at 95°C for 5 min, followed by a renaturation step at 60°C for 45 min.

5       The PCR fragments from the initial amplification and those that are subjected to the additional heating steps to permit heteroduplex formation are analyzed on a 10% polyacrylamide gel containing 7 M urea. By way of example, a 30 ml gel is prepared by combining the following  
10 ingredients:

- 12.6 g urea
- 0.75 ml 50X TAE
- 7.5 ml acrylamide:bisacrylamide (37.5:1) at 40%
- water to bring volume to 30 ml
- 15 - 30 µl Temed (added extemporaneously)
- 300 µl 10% ammonium persulfate (added extemporaneously).

After adding the Temed and ammonium persulfate, the gel is poured between two glass plates (Dcode Universal Mutation  
20 Detection System® from BIORAD) and allowed to polymerize for 1 hour.

An aliquot (7.5 µl ) of the PCR mixture is mixed with 7.5 µl of 2X sample solution (2 mM EDTA pH 8; 70% glycerol;

0.05% xylene cyanol; 0.05% bromophenol blue), and introduced into a gel well. Electrophoresis is performed for 4-5 hours at 150V in 1.25X TAE buffer with a temperature gradient ranging from 61°C to 62°C at a rate of 0.2°C per hour.

5 Following electrophoresis, the gel is incubated for 6 min. in 1.25X TAE containing 25 µg/ml ethidium bromide. Excess ethidium bromide is removed by a 20 min. wash in 1.25X TAE, and the DNA fragments are visualized with a UV transilluminator.

10 A typical TGGE result is represented in Figure 1. The amplified DNA from homozygous patients (normal or mutant) produces only one band. The amplified DNA from heterozygous patients results in three different fragments in the polyacrylamide gel. The more intense band, which migrates 15 more rapidly, corresponds to both homoduplexes, which cannot be separated in this gel. The other two bands, which migrate more slowly, correspond to both kinds of heteroduplexes.

The DNA of normal homozygous patients can be differentiated from the DNA of mutant homozygous patients by 20 analyzing the PCR fragments that were subjected to the conditions that permitted heteroduplex formation. Heteroduplexes form when the PCR amplified fragment from a normal homozygous genome is mixed with sequences from a known, mutant homozygous genome, or when the PCR amplified

fragment from a mutant homozygous genome is mixed with sequences from a known, normal homozygous genome. These heteroduplexes are visible by TGGE analysis. Consequently, the DNA of normal and mutant homozygous patients can be 5 easily differentiated by this technique using the primers described in the present study.

\* \* \*

In all the known DFNB1 families (6/6), in all but one (8/9) of the putatively DFNB1-linked families, and in about 10 half (11/21) of the families not tested for DFNB1 linkage, a mutation in Cx26 was detected. Furthermore, of the 44 chromosomes reckoned to be independent upon which a Cx26 mutant allele was identified or inferred, 33(75%) were found to carry the same deletion of a guanosine, G, at position 30 15 (30delG).

Cx26 mutations represent a major cause of recessively inherited prelingual deafness and would be implicated in about half of cases in the examined populations. In addition, one specific mutation, 30delG, accounts for the 20 majority (about three-quarters in our series) of the Cx26 mutant alleles.

The wild type connexin 26 gene published in LEE S.W. et al. (1992) J. Cell Biol. 118: 1213-1221 has the following sequence:

1 GATTTAATCC TATGACAAAC TAAGTTGGTT CTGTCTTCAC CTGTTTGTT  
51 GAGGTTGTGT AAGAGTTGGT GTTTGCTCAG GAAGAGATT AAGCATGCTT  
101 GCTTACCCAG ACTCAGAGAA GTCTCCCTGT TCTGTCCTAG CTATGTTCCCT  
151 GTGTTGTGTG CATTCGTCTT TTCCAGAGCA AACCGCCCAG AGTAGAAGATA  
201 GGATTGGGGC ACGCTGCAGA CGATCCTGGG GGGTGTGAAC AAACACTCCA  
251 CCAGCATTGG AAAGATCTGG CTCACCGTCC TCTTCATTTC TCGCATTATG  
301 ATCCTCGTTG TGGCTGCAAA GGAGGTGTGG GGAGATGAGC AGGCCGACTT  
351 TGTCTGCAAC ACCCTGCAGC CAGGCTGCAA GAACGTGTGC TACGATCACT  
401 ACTTCCCCAT CTCCCACATC CGGCTATGGG CCCTGCAGCT GATCTCGTG  
451 TCCAGCCCAG CGCTCCTAGT GGCCATGCAC GTGGCCTACC GGAGACATGA  
501 GAAGAAGAGG AAGTTCATCA AGGGGGAGAT AAAGAGTGAA TTTAAGGACA  
551 TCGAGGGAGAT CAAAACCCAG AAGGTCCGCA TCGAAGGGCTC CCTGTGGTGG  
601 ACCTACACAA GCAGCATCTT CTTCCGGTC ATCTTCGAAG CCGCCTTCAT  
651 GTACGTCTTC TATGTCATGT ACGACGGCTT CTCCATGCAG CGGCTGGTGA  
701 AGTCAACGC CTGGCCTTGT CCCAACACTG TGGACTGCTT TGTGTCCCAG  
751 CCCACGGAGA AGACTGTCTT TCACAGTGTT CATGATTGCA GTGTCTGGAA  
801 TTTGCATCCT GCTGAATGTC ACTGAATTGT GTTATTTGCT AATTAGATAT  
851 TGTTCTGGGA AGTAAAAAAA GCCAGTTAA CGCATTGCC AGTTGTTAGA  
901 TTAAGAAATA GACAGCATGA GAGGGATGAG GCAACCCGTG CTCAGCTGTC  
951 AAGGCTCAGT CGCCAGCATT TCCCAACACA AAGATTCTGA CCTTAAATGC  
1001 AACCATTTGA AACCCCTGTA GGCCTCAGGT GAAACTCCAG ATGCCACAAT  
1051 GAGCTCTGCT CCCCTAAAGC CTCAAAACAA AGGCCTAATT CTATGCCTGT  
1101 CTTAATTTTC TTTCACTTAA GTTAGTTCCA CTGAGACCCC AGGCTGTTAG  
1151 GGGTTATTGG TGTAAGGTAC TTTCATATTT TAAACAGAGG ATATCGGCAT  
1201 TTGTTTCTTT CTCTGAGGAC AAGAGAAAAA AGCCAGGTTTC CACAGAGGAC  
1251 ACAGAGAAGG TTTGGGTGTC CTCCTGGGT TCTTTTGCC AACCTTCCCC  
1301 ACGTTAAAGG TGAACATTGG TTCTTCATT TGCTTTGGAA GTTTAATCT  
1351 CTAACAGTGG ACAAAAGTTAC CAGTGCCTTA AACTCTGTTA CACTTTTG  
1401 AAGTGAAAAC TTTGTAGTAT GATAGGTTAT TTTGATGTAAG ATGTTCTG  
1451 GATACCATTA TATGTTCCCC CTGTTTCAGA GGCTCAGATT GTAATATGTA

1501 AATGGTATGT CATTGCTAC TATGATTAA TTTGAAATAT GGTCTTTGG  
1551 TTATGAATAAC TTTGCAGCAC AGCTGAGAGA GGCTGTCTGT TGTATTCAATT  
1601 GTGGTCATAG CACCTAACAA CATTGTAGCC TCAATCGAGT GAGACAGACT  
1651 AGAAGTTCCCT AGTTGGCTTA TGATAGCAAA TGGCCTCATG TCAAATATTA  
1701 GATGTAATTG TGTGTAAGAA ATACAGACTG GATGTACCCAC CAACTACTAC  
1751 CTGTAATGAC AGGCCTGTCC AACACATCTC CCTTTCCAT GCTGTGGTAG  
1801 CCAGCATCGG AAAGAACGCT GATTTAAAGA GGTGAGCTTG GGAATTTAT  
1851 TGACACAGTA CCATTTAATG GGGAGACAAA AATGGGGGCC AGGGGAGGGAA  
1901 GAAGTTTCTG TCGTTAAAAA CGAGTTGGA AAGACTGGAC TCTAAATTCT  
1951 GTTGATTAAA GATGAGCTTT GTCTACCTTC AAAAGTTGT TTGGCTTACC  
2001 CCCTTCAGCC TCCAATTTT TAAGTAAAAA TATAACTAAT AACATGTGAA  
2051 AAGAATAGAA GCTAAGGTTT AGATAAATAT TGAGCAGATC TATAGGAAGA  
2101 TTGAACCTGA ATATTGCCAT TATGCTTGAC ATGGTTCCA AAAAATGGTA  
2151 CTCCACATAG TTCAGTGAGG GTAAGTATTT TCCTGTTGTC AAGAATAGCA  
2201 TTGTAAAAGC ATTTGTAAT AATAAGAAT AGCTTAATG ATATGCTTGT  
2251 AACTAAAATA ATTTGTAAT GTATCAAATA CATTAAAAC ATTAAAATAT  
2301 AATCTCTATA AT

5       The wild type connexin 26 gene published in Kiang, D.T.  
et al. (1997) Gene 199 (1-2): 165-171; has the following  
sequence:

1   GATTTAACCC TATGACAAAC TAAGTTGGTT CTGTCTTCAC CTGTTTGTT  
10   51   GAGGTTGTGT AAGAGTTGGT GTTGCTCAG GAAGAGATT AAGCATGCTT  
101   GCTTACCCAG ACTCAGAGAA GTCTCCCTGT TCTGTCCTAG CTAGTGATTC  
151   CTGTGTTGTG TGCATTCGTC TTTTCCAGAG CAAACCGCCC AGAGTAGAAG  
15   201   ATGGATTGGG GCACGCTGCA GACGATCCTG GGGGGTGTGA ACAAACACTC

251 CACCAGCATT GGAAAGATCT GGCTCACCGT CCTCTTCATT TTTGCATTA  
301 TGATCCTCGT TGTGGCTGCA AAGGAGGTGT GGGGAGATGA GCAGGCCGAC  
5 351 TTTGTCTGCA ACACCCCTGCA GCCAGGCTGC AAGAACGTGT GCTACGATCA  
401 CTACTTCCCC ATCTCCCACA TCCGGCTATG GGCCCTGCAG CTGATCTCG  
451 TGTCCACGCC AGCGCTCCTA GTGGCCATGC ACGTGGCCTA CGGGAGACAT  
10 501 GAGAAGAAGA GGAAGTTCAT CAAGGGGGAG ATAAAGAGTG AATTTAAGGA  
551 CATCGAGGAG ATCAAAACCC AGAAGGTCCG CATCGAAGGC TCCCTGTGGT  
15 601 GGACCTACAC AAGCAGCATE TTCTTCCGGG TCATCTTCGA AGCCGCCTTC  
651 ATGTACGTCT TCTATGTCAT GTACGACGGC TTCTCCATGC AGCGGCTGGT  
20 701 GAAGTGCAAC GCCTGGCCTT GTCCCAACAC TGTGGACTGC TTTGTGTCCC  
751 GGCCCACCGA GAAGACTGTC TTTCACAGTG TTCATGATTG CAGTGTCTGG  
801 AATTTGCATC CTGCTGAATG TCACTGAATT GTGTTATTTG CTAATTAGAT  
25 851 ATTGTTCTGG GAAGTCAAAA AAGCCAGTTT AACGCATTGC CCAGTTGTTA  
901 GATTAAGAAA TAGACAGCAT GAGAGGGATG AGGCAACCCG TGCTCAGCTG  
951 TCAAGGCTCA GTCGCCAGCA TTTCCAACA CAAAGATTCT GACCTTAAAT  
30 1001 GCAACCATTG GAAACCCCTG TAGGCCTCAG GTGAAACTCC AGATGCCACA  
1051 ATGAGCTCTG CTCCCCCTAAA GCCTCAAAAC AAAGGCCTAA TTCTATGCCT  
35 1101 GTCTTAATTT TCTTCACTT AAGTTAGTTC CACTGAGACC CCAGGCTGTT  
1151 AGGGGTTATT GGTGTAAGGT ACTTTCATAT TTTAACAGA GGATATCGGC  
1201 ATTTGTTCT TTCTCTGAGG ACAAGAGAAA AAAGCCAGGT TCCACAGAGG  
40 1251 ACACAGAGAA GGTTGGGTG TCCTCCTGGG GTTCTTTTG CCAACTTCC  
1301 CCACGTTAAA GGTGAACATT GGTTCTTCA TTTGCTTGG AAGTTTAAT  
45 1351 CTCTAACAGT GGACAAAGTT ACCAGTGCCT TAAACTCTGT TACACTTTT  
1401 GGAAAGTGAAA ACTTTGTAGT ATGATAGGTT ATTTGATGT AAAGATGTT

1451 TGGATACCAT TATATGTTCC CCCTGTTCA GAGGCTCAGA TTGTAATATG  
1501 TAAATGGTAT GTCATTGCT ACTATGATT AATTGAAAT ATGGTCTTT  
5 1551 GGTTATGAAT ACTTGCGAGC ACAGCTGAGA GAGGCTGTCT GTTGTATTCA  
1601 TTGTGGTCAT AGCACCTAAC AACATTGTAG CCTCAATCGA GTGAGACAGA  
1651 CTAGAAGTTC CTAGTTGGCT TATGATAGCA AATGGCCTCA TGTCAAATAT  
10 1701 TAGATGTAAT TTTGTGTAAG AAATACAGAC TGGATGTACC ACCAACTACT  
1751 ACCTGTAATG ACAGGCCTGT CCAACACATC TCCCCTTTCC ATGCTGTGGT  
15 1801 AGCCAGCATH GGAAAGAACG CTGATTTAAA GAGGTGAGCT TGGGAATT  
1851 ATTGACACAG TACCATTAA TGGGGAGACA AAAATGGGG CCAGGGGAGG  
1901 GAGAAGTTTC TGTCGTTAAA AACGAGTTG GAAAGACTGG ACTCTAAATT  
20 1951 CTGTTGATTA AAGATGAGCT TTGTCTACCT TCAAAAGTTT GTTGGCTTA  
2001 CCCCCCTTCAG CCTCCAATTT TTTAAGTGAA AATATAACTA ATAACATGTG  
25 2051 AAAAGAATAG AAGCTAAGGT TTAGATAAT ATTGAGCAGA TCTATAGGAA  
2101 GATTGAACCT GAATATTGCC ATTATGCTTG ACATGGTTTC CAAAAAATGG  
2151 TACTCCACAT ACTTCAGTGA GGGTAAGTAT TTTCCTGTTG TCAAGAATAG  
30 2201 CATTGTAAAA GCATTTGTA ATAATAAAGA ATAGCTTTAA TGATATGCTT  
2251 GTAACAAAA TAATTTGTA ATGTATCAAA TACATTTAAA ACATTAAT  
35 2301 ATAATCTCTA TAAT

(SEQ ID No. 8). The ATG underlined in the sequences corresponds to the start codon. The guanine residue "G", which is in bold print, marks the end of the guanosine rich 40 region between nucleotides 27 and 32, inclusive.

Table 1: Mutations in the Cx26 coding exon in individuals affected with familial forms of prelingual deafness

Family (geographical origin)	30delG mutation	Other mutation	Deafness
<u>DFNB1-linked families</u>			
S15 (sTu)	homozygous	-	profound
S19 (sTu)	homozygous	-	profound
ST (sTu)	-	homozygous E47X	profound
20 (nTu)	homozygous	-	profound
60 (nTu)	homozygous	-	profound
LH (Leb)	homozygous	-	severe-profound
<u>Families consistent with DFNB1 linkage</u>			

51 (NZ)	homozygous	-	severe-profound
1160 (NZ)	homozygous	-	moderate-severe*
1548 (NZ)	-	-	profound
1608 (NZ)	homozygous	-	profound**
1773 (NZ)	heterozygous	-	profound
1873 individual II.3 (NZ)	homozygous	-	moderate
1873 individual II.2 (NZ)	-	heterozygous 30del38	profound
1877 (NZ)	homozygous	-	profound
9670 (Aust)		delE118/R14 8P	moderate-severe
<u>Families uncharacterized for DFNB1 linkage</u>			
P1 (Fr)	homozygous	-	severe-profound
P2	-	-	profound

	(Fr)			
P3	(Leb)	homozygous	-	severe-profound
P4	(Tur)	-	-	severe-profound
P5	(Fr)	homozygous	-	profound
P6	(Fr)	heterozygous	-	severe-profound
P7	(Fr)	-	-	moderate
P8	(Fr)	-	-	moderate
L13131	(Fr)	-	-	profound
L14190	(Fr)	-	-	mild-moderate
P9	(Por)	homozygous	-	severe-profound
P10	(Fr)	homozygous	-	severe-profound
P11	(Fr)	heterozygous	-	moderate-severe
P12	(Fr)	-	-	severe-profound
P13	(Fr)	-	-	profound

P14 (Alg)	heterozygous	-	moderate-severe
P15 (Fr)	-	-	severe-profound
P16 (mother/Fr, father/Pol)	homozygous	-	severe**
P17 (Fr)	heterozygous	-	severe***
1885 (NZ)	heterozygous	-	profound
2254 (NZ)	-	-	moderate-severe

The analysis reported here concerns deaf children of the various families except for family 1873 (see patients and methods).

- 5 \* moderate in one ear, severe in the other ear.  
 \*\*moderate hearing loss in mother (severe at high frequencies), \*\*\*mild hearing loss in father, who are heterozygous carriers for the 30delG mutation.
- Geographical origins: (Alg) Algeria, (Aust) Australia, (Fr)  
 10 France, (Leb) Lebanon, (NZ) New Zealand, (Pol) Poland, (Por) Portugal, (nTu) North Tunisia, (sTu) South Tunisia, (Tur) Turkey

What is claimed is:

1. A purified polynucleotide having a chain of  
5 nucleotides corresponding to a mutated sequence, which in a  
wild form encodes a polypeptide implicated in hereditary  
sensory defect, wherein said mutated purified polynucleotide  
presents a mutation responsible for prelingual non-syndromic  
deafness selected from the group consisting of a specific  
10 deletion of at least one nucleotide.

2. The purified polynucleotide according to claim 1,  
wherein the specific deletion is located in a region encoding  
connexin 26 of chromosome 13q11-12.

3. The purified polynucleotide according to claim 1 or  
15 2, wherein the specific deletion is located in a guanosine  
rich region starting at nucleotide 27, preferably at  
nucleotide 30 and extending to nucleotide 32 or nucleotide  
35, (position 1 being the first base of the initiator codon).

4. The purified polynucleotide according to any one of  
20 claims 1 to 3, wherein the specific deleted polynucleotide  
encodes a truncated polypeptide.

5. The purified polynucleotide according to any one of  
claims 1 to 3, wherein the specific deletion is a guanosine  
deletion at position 30.

25 6. The purified polynucleotide according to any one of  
claims 1 to 3, wherein specific deletion is a 38bp deletion  
beginning at position 30.

7. A purified polynucleotide, which hybridizes under  
stringent conditions specifically with a polynucleotide  
30 according to any one of claims 1 to 6.

8. An oligonucleotide useful as a primer or as a probe consisting of 15 to 50 consecutive nucleotides of the polynucleotide according to claim 7.

9. A pair of oligonucleotides according to claim 8,  
5 consisting of the following sequences:

5'-TCTTTCCAGAGCAAACCGCC (SEQ ID No. 1)-3'; and

5'-TGAGCACGGGTTGCCTCATC (SEQ ID No. 2)-3'.

10. The oligonucleotide according to claim 8, which has a sequence selected from the group consisting of:

10 5'-AGACGATCCTGGGGGTGTGAACAAA (SEQ ID No. 5)-3';

5'-ATCCTGGGGGTGTGA (SEQ ID No. 6)-3'; and

5'-AGACGATCCTGGGGCTCACCGTCCTC (SEQ ID No. 7)-3'.

11. A pair of the oligonucleotides as claimed in claim 8, which are:

15 5'-CTAGTGATTCTGTGTTGTGC (SEQ ID No. 9)-3'; and

5' ATAATGCGAAAAATGAAGAGGA (SEQ ID No. 10)-3'.

12. A pair of oligonucleotides as claimed in claim 8, which are:

20 5'-CGCCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCCTAGTGATTCT  
GTGTTGTGTGC (SEQ ID No. 14)-3'; and

5' ATAATGCGAAAAATGAAGAGGA (SEQ ID No. 10)-3'.

13. A method for the detection of an hereditary sensory defect, the autosomal prelingual non-syndromic deafness, for homozygous and heterozygous individuals in a biological sample containing DNA, comprising the steps of:

a) bringing the biological sample into contact with oligonucleotide primers according to any one of claims 8 to 12, the DNA contained in the sample having been optionally made available to hybridization and under conditions permitting a hybridization of the primers with the DNA contained in the biological sample;

b) amplifying the DNA;

- c) revealing the amplification products; and
- d) detecting the mutation by appropriate techniques.

14. The method of claim 13, wherein in step d) the mutation is detected by one of the following techniques:

- 5 - single-strand conformation polymorphism (SSCP); or
- denaturing gradient gel electrophoresis (DGGE); or
- sequencing or
- temperature gradient gel electrophoresis (TGGE).

15. The method according to claim 13 or 14, wherein  
10 step c) comprises the detection of the amplified products with an oligonucleotide probe according to any one of claims 8, 9, or 10.

16. A method for the detection of an hereditary sensory defect, the autosomal prelingual non-syndromic deafness, for  
15 homozygous and heterozygous individuals in a biological sample containing DNA, comprising the steps of:

- a) bringing the biological sample into contact with an oligonucleotide probe according to any one of claims 8 to 12, the DNA contained in the sample having been optionally made  
20 available to hybridization and under conditions permitting a hybridization of the primers with the DNA contained in the biological sample; and
- b) detecting the hybrid formed between the oligonucleotide probe and the DNA contained in the biological  
25 sample.

17. The method according to any one of claims 13 to 16, wherein before step a), the DNA contained in the biological sample is amplified using a pair of primers.

18. The method of any one of claims 13 to 15, wherein  
30 step d) further comprises the steps of:

- a) incubating the amplification products with a labeled detection probe that hybridizes with both a normal Cx26

sequence and a 30delG mutant sequence and a first capture probe that hybridizes with said normal Cx26 sequence but does not hybridize with said 30delG mutant sequence;

- 5        b) incubating the amplification products with said labeled detection probe and a second capture probe that hybridizes with said mutant 30delG sequence but does not hybridize with said normal Cx26 sequence;
- 10      c) hybridizing the amplification products with said detection probe and with said first or second capture probe; and
- 15      d) comparing the hybridization signal obtained from said first capture probe with the hybridization signal obtained from said second capture probe.

19. The method of claim 18, wherein in step a) the biological sample is brought into contact with the pair of oligonucleotide primers as claimed in claim 12.

20. The method of claim 18 or 19, wherein said first capture probe is 5'-AAAAAAAATCCTGGGGGGTGTG (SEQ ID No. 11)-3' and said second capture probe is 5'-AAAAAAAATCCTGGGGGTGTGA (SEQ ID No. 12)-3'.

21. The method of any one of claims 18 to 20, wherein said detection probe is 5-CAGCATTGGAAAGATCTGGCTCA (SEQ ID No. 13)-3'.

22. The method of any one of claims 18 to 21, wherein said detection probe is non-radioactively labeled.

23. The method of claim 22, wherein said detection probe is labeled with biotin.

24. The method of any one of claims 18 to 23, wherein said first and second capture probes are bound to a microplate.

25. The method of claim 13, wherein in step a) the biological sample is brought into contact with the pair of oligonucleotide primers according to claim 12.

26. The method of claim 25 further comprising between 5 step b) and step c):

incubating the amplified DNA with either a first nucleotide sequence from a known, normal homozygous Cx26 sample or a second nucleotide sequence from a known mutant Cx26 sample; and

10 hybridizing the amplified DNA with either said first nucleotide sequence or said second nucleotide sequence.

27. The method of claim 25 or 26, wherein step d) comprises analyzing the hybridized DNA to differentiate 15 between DNA from normal homozygous Cx26 individuals and DNA from mutant homozygous Cx26 individuals.

28. A kit for the detection of an hereditary sensory defect, the autosomal prelingual non-syndromic deafness, for homozygous and heterozygous individuals, said kit comprising:

20 a) oligonucleotides as claimed in any one of claims 8, 9, 10, 11 or 12;

b) reagents necessary for carrying out a DNA amplification; and

25 c) a component that makes it possible to determine the length of the amplified fragments or to detect a mutation.

1 / 1




Figure 1